

JUL 20 2006

Atty Docket No. 021044-007310U3

PTO FAX NO.: 1-571-273-0835

ATTENTION: Examiner Gary Nickol

Group Art Unit 1646

**OFFICIAL COMMUNICATION**  
**FOR THE PERSONAL ATTENTION OF**  
**EXAMINER Gary Nickol**

**CERTIFICATION OF FACSIMILE TRANSMISSION**


I hereby certify that the following documents in re Application of Brian Wong et al., Application No. 10/039,761, filed October 19, 2001 for MODULATORS OF LEUKOCYTE ACTIVATION, COMPOSITIONS AND METHODS OF USE are being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Documents Attached

1. Amendment after Allowance under 37 CFR §1.312(a)

Number of pages being transmitted, including this page: 6

Dated: July 20, 2006

  
Jo Ann Honcik Dallara for  
Beth L. Kelly, Reg. 51,868

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY  
RETURN FACSIMILE AT (415) 576-0300**

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, CA 94111-3834  
Telephone: 415-576-0200  
Fax: 415-576-0300  
0860

60826844 v1

JUL 20 2006

I hereby certify that this correspondence is being sent via facsimile to  
Examiner Gary Nickol at 1-571-273-0835 addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On July 20, 2006

TOWNSEND and TOWNSEND and CREW LLP

By: 

Jo Ann Honcik Dallara

PATENT

Attorney Docket No.: 021044-007310US  
Client Ref. No.: P.0061.01.US.UT.X00.RR

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Brian Wong et al.

Application No.: 10/039,761

Filed: October 19, 2001

For: MODULATORS OF LEUKOCYTE  
ACTIVATION, COMPOSITIONS AND  
METHODS OF USE

Customer No.: 20350

Confirmation No. 9200

Examiner: Gary Nickol

Technology Center/Art Unit: 1646

AMENDMENT AFTER ALLOWANCE  
UNDER 37 CFR § 1.312(a)

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Notice of Allowance mailed October 28, 2005, please amend  
the above-identified application as follows:

**Amendments to the Specification** begin on page 2 of this paper.

**Remarks/Arguments** begin on page 5 of this paper.